Anders Bjartell
Overview
Explore the profile of Anders Bjartell including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
295
Citations
6514
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sharifi M, Feng E, Rydzewski N, Taylor A, Sperger J, Shi Y, et al.
Mol Oncol
. 2025 Feb;
PMID: 39985777
Metastatic castration-resistant prostate cancer (mCRPC) is a heterogeneous disease. Several studies have identified transcriptional subtypes of mCRPC, but comprehensive analysis of prognostic gene expression pathways has been limited. Therefore, we...
2.
Bjartell A, Krzyzanowska A, Liu V, Tierney M, Royce T, Sjostrom M, et al.
Clin Cancer Res
. 2025 Feb;
PMID: 39983011
Purpose: A multimodal artificial intelligence (MMAI) biomarker was developed using clinical trial data from North American men with localized prostate cancer (PCa) treated with definitive radiation, using biopsy digital pathology...
3.
Krzyzanowska A, Higgins D, Barron S, Loughman T, ONeill A, Sheehan K, et al.
BJUI Compass
. 2025 Jan;
6(1):e474.
PMID: 39877562
Objectives: This study aimed to clinically validate the six-gene prognostic molecular clinical risk score (MCRS) for the prediction of aggressive prostate cancer in diagnostic biopsy tissue. Methods: MCRS was evaluated...
4.
de Vos I, Nieboer D, Frydenberg M, Pavlovich C, Van Hemelrijck M, Lee L, et al.
JAMA Netw Open
. 2025 Jan;
8(1):e2454366.
PMID: 39820695
Importance: Active surveillance (AS) for patients with prostate cancer (PC) often includes fixed repeat prostate biopsies that do not account for the varying risk of reclassification to significant disease. Given...
5.
Hvittfeldt E, Hedeer F, Thimansson E, Sandeman K, Minarik D, Ingvar J, et al.
EJNMMI Rep
. 2025 Jan;
9(1):1.
PMID: 39747706
Background: Positron emission tomography/computed tomography (PET/CT) with prostate specific membrane antigen ligands (PSMA) is established for use in primary staging of prostate cancer to screen for metastases. It has also...
6.
Sakalis V, Bhattacharya Y, Beyer K, Murray C, Smith E, Willemse P, et al.
Eur Urol Open Sci
. 2024 Nov;
70:183-193.
PMID: 39611162
Background And Objective: Clinical practice guidelines for prostate cancer (PCa) are a valuable resource for everyday clinical practice. The clinical practice guidelines and recommendations produced by various societies should demonstrate...
7.
Bialas P, Kobayashi T, Hellsten R, Krzyzanowska A, Persson M, Marginean F, et al.
Prostate
. 2024 Nov;
85(3):252-264.
PMID: 39523927
Background: The transcription factor Signal Transducer and Activator of Transcription 3 (STAT3) plays a role in carcinogenesis and is involved in processes, such as proliferation, differentiation, drug resistance and immunosuppression....
8.
Thimansson E, Zackrisson S, Jaderling F, Alterbeck M, Jiborn T, Bjartell A, et al.
Acta Oncol
. 2024 Oct;
63:816-821.
PMID: 39473176
Objectives: To evaluate the feasibility of AI-assisted reading of prostate magnetic resonance imaging (MRI) in Organized Prostate cancer Testing (OPT). Methods: Retrospective cohort study including 57 men with elevated prostate-specific...
9.
Twilt J, Saha A, Bosma J, van Ginneken B, Bjartell A, Padhani A, et al.
Eur Urol
. 2024 Oct;
87(2):240-250.
PMID: 39438187
Background And Objective: Biparametric magnetic resonance imaging (bpMRI), excluding dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI), is a potential replacement for multiparametric MRI (mpMRI) in diagnosing clinically significant prostate cancer...
10.
Gillessen S, Turco F, Davis I, Efstathiou J, Fizazi K, James N, et al.
Eur Urol
. 2024 Oct;
87(2):157-216.
PMID: 39394013
Background And Objective: Innovations have improved outcomes in advanced prostate cancer (PC). Nonetheless, we continue to lack high-level evidence on a variety of topics that greatly impact daily practice. The...